Cannabics Pharmaceuticals Inc. , a global leader in the development of cancer related cannabinoid-based medicine, released today the interim results of its second in-vivo POC study evaluating the efficacy of company’s proprietary drug candidate RCC-33 for the treatment of colorectal cancer on mice. The study objective was to evaluate the potential efficacy of the RCC-33 drug candidate as a systemic treatment for colorectal cancer when administered orally. Interim study results confirmed the potential efficacy of RCC-33 as a systemic treatment for colorectal cancer when administered orally, showing a 30% reduction in tumor volume in comparison with sham control mice, after 24 days of treatment. The results indicated statistical significance with a p-value less than 0.05.
The announcement comes following previously released in-vivo study results demonstrating a 33% reduction in tumor volume in mice treated with RCC-33 using intraperitoneal (IP) injection.
Gabriel Yariv, Cannabics Pharmaceuticals President & COO said: “Our first POC study in mice demonstrated that RCC-33 has potential anti-tumor effect on colorectal cancer. During the first POC study we used intraperitoneal (IP) administration, via injection to the abdomen, and while we were very pleased to see a 33% reduction in tumor volume, we did not know how RCC-33 would work when administered orally for systemic treatment. The leap between IP to oral administration is not a straightforward process, and it necessitated a great deal of attention. Today, after having seen the interim results, this second POC study is immensely important to us, as it reconfirms the potential of RCC-33 as a treatment candidate for colorectal cancer, as well as being efficacious via oral administration. This is another important step for us in the right direction”.
Eyal Ballan Cannabics Pharmaceuticals CTO said “These positive results move us one step closer to in-human studies. After seeing the antitumor effect reconfirmed in this POC study, our next goal is to improve the bioavailability of the drug to be administered in our upcoming clinical studies”.
About Cannabics Pharmaceuticals:
Cannabics Pharmaceuticals Inc. is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com.
For more information about Cannabics:
Cannabics Pharmaceuticals Inc.
Phone: +1-(877)-424-2429
info@Cannabics.com
http://www.Cannabics.com